

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



BeOne Medicines Ltd.

百濟神州有限公司

(a corporation incorporated under the laws of Switzerland)

(Stock Code: 06160)

ISSUE OF NEW SHARES UNDER THE SHARE SCHEME

ISSUE OF NEW SHARES UNDER THE 2018 ESPP

Reference is made to the announcement of BeOne Medicines Ltd. (the “**Company**”) filed with the Stock Exchange on March 10, 2026 in respect of purchase of Shares pursuant to the current offering period from March 2, 2026 to August 31, 2026 under the 2018 ESPP (the “**Current Offering Period**”).

The Company announces that pursuant to its authorization to increase or reduce the share capital within the capital band as set out in Article 4a of the Swiss Articles, as approved by the Company’s shareholders at the EGM, the Company will increase its share capital by issuing 866,073 new Shares (the “**New Shares**”) to BGNC2 (a wholly-owned subsidiary of the Company) (the “**Share Issuance**”). Upon issuance, the New Shares will be re-transferred to the Company and held for the benefit of the Participants under the 2018 ESPP to deliver the number of Shares purchased by such Participants at the end of the Current Offering Period. The actual number of New Shares to be delivered to the Participants will be based on the number of Shares purchased at the end of the Current Offering Period, which may be less than 866,073 New Shares. The Share Issuance will be made under the scheme mandate limit approved by the Company’s shareholders at the annual general meeting of the Company held on June 11, 2026.

As at the date of this announcement, the Participants comprise approximately 4,694 individuals, who are eligible employees of the Company and Designated Subsidiaries.

The New Shares, when issued and fully paid, will rank pari passu in all respects among themselves and with all other issued Shares at the time of allotment, except that the New Shares shall, while held by BGNC2 or the Company, not have any voting rights and shall not have any rights to receive dividends to the extent that the relevant dividend resolution by shareholders does not grant dividend rights to Shares held by subsidiaries or the Company. In accordance with Rule 17.05A of the HK Listing Rules, BGNC2 and the Company shall not exercise any voting rights in respect of the New Shares. In addition to the limitation under applicable law, BGNC2 and the Company undertake that they will not exercise any voting rights nor receive any dividend in respect of the New Shares held by them.

The New Shares issued will not be considered to be outstanding under the laws of Switzerland and therefore, these New Shares would not have any dilutive impact to the shareholdings of the Company's shareholders, until being delivered to the Participants.

AMENDMENTS TO THE SWISS ARTICLES

In connection with the Share Issuance, the Company will also make corresponding amendments to Articles 4 and 4a para. 1 of the Swiss Articles to reflect such capital increase, as set out in the appendix to this announcement.

The amended Swiss Articles will be filed with the Stock Exchange upon completion of the Share Issuance and the amended Swiss Articles becoming effective.

INFORMATION OF BGNC2 AND THE COMPANY

BGNC2

BGNC2 is a company incorporated in the Cayman Islands with limited liability. As at the date of this announcement, it is a direct wholly-owned subsidiary of the Company and is principally engaged in financial holding company activities.

The Company

The Company is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.

REASONS FOR AND BENEFITS OF THE ISSUE OF NEW SHARES

The New Shares shall be utilized to satisfy obligations to deliver Shares in connection with purchase of Shares under the 2018 ESPP. The Share Issuance is expected to simplify and streamline the administrative procedures for delivering Shares to the Participants at the end of the Current Offering Period.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context otherwise requires.

“2018 ESPP”	the Sixth Amended and Restated 2018 Employee Share Purchase Plan approved by the shareholders of the Company on June 11, 2026, as amended from time to time, the principal terms of which were set out in the Company’s Proxy Statement/Circular dated April 28, 2026
“BGNC2”	BG NC 2, Ltd., a company incorporated in the Cayman Islands with limited liability, and is wholly owned by the Company as at the date of this announcement
“Board”	the board of Directors
“Company”	BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland and listed on the Stock Exchange (Stock Code: 06160), Nasdaq (Trading Symbol: ONC) and Shanghai Stock Exchange STAR Market (Stock Code: 688235)
“Current Offering Period”	the current offering period under the 2018 ESPP which commenced on March 2, 2026 and will end on August 31, 2026
“Designated Subsidiary(ies)”	the subsidiary of the Company that has been designated by the administrator of the 2018 ESPP to participate in the 2018 ESPP
“Director(s)”	the director(s) of the Company
“EGM”	an extraordinary general meeting of the Company held on April 28, 2025 for the purpose of, inter alia, considering and approving the Swiss Articles
“HK Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Nasdaq”	The Nasdaq (National Association of Securities Dealers Automated Quotation System) Global Select Market in the United States
“New Shares”	866,073 new Shares to be allotted and issued by the Company to BGNC2 and re-transferred to the Company for the purpose of satisfying Shares to be purchased by the Participants at the end of the Current Offering Period
“Participants”	the employee(s) of the Company and Designated Subsidiaries who are eligible to participate in the 2018 ESPP

“Share(s)”	ordinary share(s) of US\$0.0001 each in the share capital of the Company
“STAR Market”	the Science and Technology Innovation Board of the Shanghai Stock Exchange
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Swiss Articles”	the articles of association adopted by the Company in compliance with the laws of Switzerland effective on May 27, 2025, as amended from time to time
“United States”	the United States of America
“US\$”	United States dollars, the lawful currency of the United States

By order of the Board
BeOne Medicines Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, July 30, 2026

As of the date of this announcement, the Board of Directors of the Company consists of Mr. John V. Oyler as Chairman and Executive Director, Dr. Felix J. Baker and Dr. Xiaodong Wang as Non-executive Directors, and Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp as Independent Non-executive Directors.

APPENDIX
AMENDMENTS TO THE SWISS ARTICLES

Prior to the amendments	After the amendments
Article 4 Share Capital The share capital of the Company is USD 154,097.5898 and is divided into 1,540,975,898 fully paid-up registered shares with a nominal value of USD 0.0001 each (each a Share and collectively the Shares).	Article 4 Share Capital The share capital of the Company is USD ~~154,097.5898~~154,184.1971 and is divided into ~~1,540,975,898~~1,541,841,971 fully paid-up registered shares with a nominal value of USD 0.0001 each (each a Share and collectively the Shares).
Article 4a Capital Band ¹The Company has a capital band ranging from USD 138,687.8308 (lower limit) to USD 231,146.3847 (upper limit). The Company's Board of Directors (the Board) is authorized to increase or reduce the share capital within the capital band at any time or from time to time and in any (partial) amounts, or to cause the Company or any of its group companies to directly or indirectly acquire registered shares with a nominal value of USD 0.0001 each (including under a share repurchase program), until April 28, 2029. A capital increase may be effected by issuing up to 770,487,949 fully paid-in registered shares with a nominal value of USD 0.0001 each, and a capital reduction by cancelling up to 154,097,590 registered shares with a nominal value of USD 0.0001 each. A capital increase or reduction may also be effected by an increase or a reduction of the nominal value of the existing Shares, or by a simultaneous reduction and re-increase of the share capital. The number of new Shares to be issued or to be cancelled is subject to upward or downward adjustment by the Board, if the Board issues or cancel Shares within the capital band pursuant to its authority under this Article 4a.	Article 4a Capital Band ¹The Company has a capital band ranging from USD 138,687.8308 (lower limit) to USD 231,146.3847 (upper limit). The Company's Board of Directors (the Board) is authorized to increase or reduce the share capital within the capital band at any time or from time to time and in any (partial) amounts, or to cause the Company or any of its group companies to directly or indirectly acquire registered shares with a nominal value of USD 0.0001 each (including under a share repurchase program), until April 28, 2029. A capital increase may be effected by issuing up to ~~770,487,949~~769,621,876 fully paid-in registered shares with a nominal value of USD 0.0001 each, and a capital reduction by cancelling up to ~~154,097,590~~154,963,663 registered shares with a nominal value of USD 0.0001 each. A capital increase or reduction may also be effected by an increase or a reduction of the nominal value of the existing Shares, or by a simultaneous reduction and re-increase of the share capital. The number of new Shares to be issued or to be cancelled is subject to upward or downward adjustment by the Board, if the Board issues or cancel Shares within the capital band pursuant to its authority under this Article 4a.